Analysts Offer Predictions for INmune Bio, Inc.’s Q2 2022 Earnings (NASDAQ:INMB)

INmune Bio, Inc. (NASDAQ:INMBGet Rating) – B. Riley increased their Q2 2022 earnings per share (EPS) estimates for INmune Bio in a research note issued to investors on Wednesday, May 11th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.58) per share for the quarter, up from their prior estimate of ($0.68). B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for INmune Bio’s Q3 2022 earnings at ($0.77) EPS, Q4 2022 earnings at ($0.42) EPS, FY2022 earnings at ($2.02) EPS, FY2023 earnings at ($1.60) EPS and FY2024 earnings at ($1.52) EPS.

INmune Bio (NASDAQ:INMBGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. During the same quarter in the prior year, the company posted ($0.32) EPS.

Several other research analysts have also weighed in on the stock. Maxim Group assumed coverage on shares of INmune Bio in a research note on Friday, May 6th. They issued a “buy” rating and a $22.00 price objective on the stock. Zacks Investment Research upgraded shares of INmune Bio from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 10th.

Shares of NASDAQ:INMB opened at $6.64 on Friday. INmune Bio has a fifty-two week low of $6.18 and a fifty-two week high of $30.37. The company has a quick ratio of 23.89, a current ratio of 23.89 and a debt-to-equity ratio of 0.19. The firm has a 50-day simple moving average of $7.71 and a 200 day simple moving average of $10.06.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. increased its holdings in shares of INmune Bio by 238.3% in the first quarter. Westside Investment Management Inc. now owns 26,390 shares of the company’s stock worth $222,000 after acquiring an additional 18,590 shares in the last quarter. Fermata Advisors LLC increased its holdings in shares of INmune Bio by 9.1% in the first quarter. Fermata Advisors LLC now owns 19,586 shares of the company’s stock worth $165,000 after acquiring an additional 1,631 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of INmune Bio in the fourth quarter worth about $175,000. BlackRock Inc. increased its holdings in shares of INmune Bio by 59.3% in the fourth quarter. BlackRock Inc. now owns 233,265 shares of the company’s stock worth $2,379,000 after acquiring an additional 86,836 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of INmune Bio by 338.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,509 shares of the company’s stock worth $118,000 after acquiring an additional 8,882 shares in the last quarter. Institutional investors and hedge funds own 13.91% of the company’s stock.

About INmune Bio (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

See Also

Earnings History and Estimates for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.